Sign up Australia
Proactive Investors - Run By Investors For Investors

Viralytics bags $4M to advance cancer treatment

Viralytics bags $4M to advance cancer treatment

Following applications well in excess of A$10 million, Viralytics (ASX:VLA) has raised a total of $4 million via a share purchase plan to retail investors priced at $0.615 per share.

Viralytics stock was last trading at A$0.70, representing a 23% improvement over the past three months.

This is in addition to the successful placement that raised $28.4 million at the same price per share in December 2015.

That financing attracted a range of specialist healthcare investment funds, including a substantial commitment from OrbiMed Advisors, a new participant.

The funds from this capital raise will enable Viralytics to more rapidly advance its broad clinical program for CAVATAK, an oncolytic virus and the company’s lead product candidate.

CAVATAK is currently being studied in Phase 1 and 2 clinical trials for the treatment of melanoma, as well as prostate, bladder and lung cancers.

Intratumoural, intravenous and intravesicular delivery routes are also under investigation.

Two combination studies with checkpoint inhibitors are underway in late-stage melanoma patients.

The capital raise is interpreted as placing Viralytics in a position of financial security from which it can continue to build its clinical program while also increasing engagement with major pharmaceutical entities.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

View full VLA profile View Profile

Viralytics Timeline

Newswire
December 10 2015

Related Articles

couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
copd on an iPad
March 15 2018
Chairman Simon Shaw said: "Synairgen ended 2017 in a strong position"

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use